The DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Gene Therapy Using Adeno-Associated Virus Vectors
Open accessAbstract
SUMMARY: The unique life cycle of adeno-associated virus (AAV) and its ability to infect both nondividing and dividing cells with persistent expression have made it an attractive vector. An additional attractive feature of the wild-type virus is the lack of apparent pathogenicity. Gene transfer studies using AAV have shown significant progress at the level of animal models; clinical trials have been noteworthy with respect to the safety of AAV vectors. No proven efficacy has been observed, although in some instances, there have been promising observations. In this review, topics in AAV biology are supplemented with a section on AAV clinical trials with emphasis on the need for a deeper understanding of AAV biology and the development of efficient AAV vectors. In addition, several novel approaches and recent findings that promise to expand AAV's utility are discussed, especially in the context of combining gene therapy ex vivo with new advances in stem or progenitor cell biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The virus itself is able to efficiently infect cells while provoking little to no innate or adaptive immune response or associated toxicity, at least upon first treatment with a serotype (Daya and Berns, 2008).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Daya and Berns, 2008
In the citing paper
“Eighty-four percent of genome sequence homology exists between AAV2 and AAV9, whereas the sequences of AAV2 and AAV5 have a 54% homology and AAV9 and AAV5 have a 46% homology.38,39”
From Systemic and local immune responses to intraocular AAV vector administration in non-human primates (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 1×
“AAV-2 gains entry into target cells by using the cellular receptor heparan sulfate proteoglycan ( 62 ).”
BackgroundKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Site-specific integration by adeno-associated virus.
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., & Berns, K. I. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.6.2211 · Cited by 868
Self-citationSite-specific integration by adeno-associated virus.
Linden, R. M., Ward, P., Giraud, C., Winocour, E., & Berns, K. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11288 · Cited by 805
Self-citationFerrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“Inefficient AAV trafficking (30) and second-strand synthesis (19) have been identified as being ratelimiting factors in AAV gene expression.”
BackgroundAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Research works printed but not linked: 1
- Fischer, A., S. Hacein-Bey-Abina, C. Lagresle, A. Garrigue, and M. Cavazana-Calvo. 2005. Gene therapy of severe combined immunodeficiency disease: proof of efficiency and safety issues. Bull. Acad. Natl. Med.189:779-785. (In French.)
Cited by
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
“The virus itself is able to efficiently infect cells while provoking little to no innate or adaptive immune response or associated toxicity, at least upon first treatment with a serotype (Daya and Berns, 2008).”
BackgroundTherapeutic strategies for enhancing angiogenesis in wound healing
Veith, A. P., Henderson, K., Spencer, A., Sligar, A. D., & Baker, A. B. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.010 · Cited by 1,021
“These viruses are characterized by low immunogenicity and the need for a helper virus to replicate [217].”
BackgroundMethodThe war against heart failure: the Lancet lecture
Braunwald, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61889-4 · Cited by 811
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
“The therapeutic expression cassette replaces rep and cap , leaving the viral inverted terminal repeats as the only viral sequence”
BackgroundAurnhammer, C., Haase, M., Muether, N., Hausl, M., Rauschhuber, C., Huber, I., Nitschko, H., Busch, U., Sing, A., Ehrhardt, A., et al. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.034 · Cited by 490
“…of AAV replication, the ITR sequences play a critical role as origins of replication, serving as priming sequences for the host cell DNA polymerase during second-strand synthesis, as well as being essential for genome packaging (Yan et al. , 2005; McAlister and Owens, 2007; Daya and Berns, 2008).”
Influential
Metadata
- Authors
- Daya, S., & Berns, K. I.
- Affiliations
- University of Florida (US)
- Corresponding author
- Berns, Kenneth I.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2008-10
- Volume
- 21
- Issue
- 4
- Pages
- 583-593
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- PMC
- PMC2570152
- OpenAlex
- W2114741749
- Cited by
- 926
- References
- 84
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 53 · 2023: 47 · 2022: 62 · 2021: 71 · 2020: 77 · 2019: 67 · 2018: 71 · 2017: 64 · 2016: 56 · 2015: 56 · 2014: 44 · 2013: 38 · 2012: 46
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Clinical Microbiology Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, DK58327)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus, gene therapy vectors, persistent gene expression, vector safety, ex vivo gene therapy, stem cell gene therapy, progenitor cells
- MeSH terms
- Dependovirus, Animals, Humans, Transduction, Genetic, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene Therapy Using Adeno-Associated Virus Vectors. https://app.cochat.ai/papers/10.1128/cmr.00008-08
- The paper
- Daya, S., & Berns, K. I. (2008). Gene Therapy Using Adeno-Associated Virus Vectors. Clinical Microbiology Reviews. https://doi.org/10.1128/cmr.00008-08
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.